Stock CLDX CELLDEX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
36.3 USD +0.11% Intraday chart for Celldex Therapeutics, Inc. -4.42% -8.47%
17/04 Sector Update: Health Care Stocks Mixed Wednesday Afternoon MT
17/04 Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise MT

Business Summary

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Number of employees: 160

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapeutics
100.0 %
2 100.0 % 7 100.0 % +192.02%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
2 100.0 % 7 100.0 % +192.02%

Managers

Managers TitleAgeSince
Tibor Keler FOU
 Founder 65 01/83/01
Anthony Marucci FOU
 Founder 62 01/83/01
Sam Martin DFI
 Director of Finance/CFO 53 01/09/01
Diane Young CTO
 Chief Tech/Sci/R&D Officer 68 08/19/08
Sarah Boylan Cavanaugh ADM
 Chief Administrative Officer 49 01/12/01
Freddy Jimenez LAW
 General Counsel 55 01/16/01
Margo Heath-Chiozzi LAW
 General Counsel 67 03/17/03
Richard Wright PRN
 Corporate Officer/Principal 60 01/12/01
Elizabeth Crowley PRN
 Corporate Officer/Principal 52 01/09/01
Ronald A. Pepin PRN
 Corporate Officer/Principal 68 07/11/07

Members of the board

Members of the board TitleAgeSince
Herbert Conrad BRD
 Director/Board Member 91 01/08/01
Cheryl L. Cohen BRD
 Director/Board Member 58 16/22/16
Harry H. Penner BRD
 Director/Board Member 78 01/97/01
James Marino BRD
 Director/Board Member 74 08/17/08
Karen Lipton Shoos CHM
 Chairman 70 01/01/01
Anthony Marucci FOU
 Founder 62 01/83/01
Garry Neil BRD
 Director/Board Member 70 16/22/16
Keith L. Brownlie BRD
 Director/Board Member 71 15/17/15
Rita Jain BRD
 Director/Board Member 62 16/23/16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 64,403,377 65,686,894 ( 101.99 %) 0 101.99 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
10.94 %
7,050,409 10.94 % 296 M $
Wellington Management Co. LLP
10.05 %
6,476,561 10.05 % 272 M $
Eventide Asset Management LLC
5.635 %
3,630,013 5.635 % 152 M $
BlackRock Advisors LLC
5.405 %
3,481,916 5.405 % 146 M $
RTW Investments LP
5.376 %
3,463,201 5.376 % 145 M $
POLAR CAPITAL HOLDINGS PLC
4.868 %
3,135,871 4.868 % 132 M $
Vanguard Fiduciary Trust Co.
4.729 %
3,046,331 4.729 % 128 M $
Kynam Capital Management LP
4.666 %
3,005,904 4.666 % 126 M $
Point72 Asset Management LP
4.278 %
2,756,122 4.278 % 116 M $
Bellevue Asset Management AG
3.751 %
2,416,296 3.751 % 101 M $

Company contact information

Celldex Therapeutics, Inc.

Perryville III Building 53 Frontage Road

08827, Hampton

+908 200 7500

http://www.celldex.com
address Celldex Therapeutics, Inc.(CLDX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Celldex Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
36.3 USD
Average target price
70.71 USD
Spread / Average Target
+94.81%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CELLDEX THERAPEUTICS, INC. Stock Celldex Therapeutics, Inc.
-8.47% 2.39B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CLDX Stock
  4. Company Celldex Therapeutics, Inc.